Citation data

CrossRef

Works that cite this article, indexed by Crossref.

25 resultsUpdated August 16, 2026
1

Impact of newer direct-acting antiviral drugs based on quality-adjusted life years

Perspectives in Clinical Research 12(2) (2021)

Bhavya H. Vyas; Nishita H. Darji; Devang A. Rana; Kaushal Y. Vyas; Supriya D. Malhotra

2

Societal Economic Burden of Cystic Fibrosis in Iran: A Cost-of-Illness Study

Journal of Health Economics and Outcomes Research 12(2) (2025)

Hassan Karami; Shideh Rafati; Maryam Shirvani Shiri; Ali Mouseli; Hedayat Salari; Amin Ghanbarnejad; Mitra Nowrouzpour; Fatemeh Noroozian; Ali Alizadeh; Fatemeh Asadi; Narges Salehi

3

The Estimation of Economic Burden of Hepatitis B Virus Infection in Iran

Hepatitis Monthly 17(1) (2017)

Mehdi Mohammadzadeh; Behnaz Fattahi; Tayebeh Ghari

4

Socio-economic assessments of Hepatitis C Virus infection: Evidence from Vehari district of Pakistan

Archives of Hepatitis Research (2021)

Ahmed Dilshad; Shakeel Muhammad; Tariq Bilal; Mahmood Tariq

6

Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme

International Journal of Clinical Pharmacy 43(4) (2021)

Salamat Ali; Tofeeq Ur-Rehman; Mashhood Ali; Sayeed Haque; Faisal Rasheed; Eleri Lougher; Muhammad Sarfraz Nawaz; Vibhu Paudyal

7

Prevalence of HBV, HCV, and HIV Infections among Patients Undergoing Hemodialysis in Fasa, Iran: A Six-Year Follow-up Study

Middle East Journal of Digestive Diseases 14(3) (2022)

Seyedeh Azra Shamsdin; Mohamad Reza Fatahi; Ali Reza Ansari; Ali Reza Safarpour

8

Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia

Hepatitis Monthly 18(1) (2018)

Ligita Jancoriene; Katazyna Polubenko; Edita Kazenaite; Arida Buivydiene; Jolita Jakutiene; Ieva Tolmane; Agita Jeruma; Daiva Radzisauskiene; Evelina Mockiene; Arvydas Ambrozaitis

9

Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review

PharmacoEconomics 38(9) (2020)

T. Joseph Mattingly; Bryan L. Love; Bilal Khokhar

10

Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS)

BMC Research Notes 14(1) (2021)

Fariborz Mansour-Ghanaei; Farahnaz Joukar; Mohammadreza Naghipour; Soheil Hassanipour; Sara Yeganeh; Masood Sepehrimanesh; Mohammad Fathalipour

11

Evaluating the Prevalence of HBV, HCV, and HIV in Hemodialysis Patients in North Cyprus

Hepatitis Monthly In Press(In Press) (2019)

Meryem Güvenir; Emrah Guler; Deren Oygar; Ahmet Behlul; Kaya Suer

12

The role of insurance providers in supporting treatment and management of hepatitis C patients

BMC Health Services Research 19(1) (2019)

Masoud Behzadifar; Hasan Abolghasem Gorji; Aziz Rezapour; Meysam Behzadifar; Nicola Luigi Bragazzi

13

Economic Burden of Inflammatory Bowel Disease in Shiraz, Iran

Archives of Iranian Medicine 26(1) (2023)

Leila Rahmati; Alireza Mooghali; Seyed Mohammad Hosein Kamani; Fatemeh Zare; Hassan Askari; Ali Reza Safarpour

14

Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study

Therapeutic Apheresis and Dialysis 25(2) (2021)

Shahab Mahmoudvand; Somayeh Shokri; Azarakhsh Azaran; Seyed S. Seyedian; Manoochehr Makvandi; Habibollah Mirzaei; Sheida B. Sheikhrobat

15

The Evaluation of Interferon Lambda 4 rs368234815 as a Predictor Factor in Treated Patients with Chronic Hepatitis C Genotype 1a Infection

Indian Journal of Medical Microbiology 35(2) (2017)

Shahram Jalilian; Seyed Mahmoud Latifi; Manoochehr Makvandi; Ali Teimoori; Azarakhsh Azaran; Mehdi Parsanahad; Gholamabas Kayedani

16

Hepatitis C virus-related policy-making in Iran: a stakeholder and social network analysis

Health Research Policy and Systems 17(1) (2019)

Masoud Behzadifar; Hasan Abolghasem Gorji; Aziz Rezapour; Alireza Rezvanian; Nicola Luigi Bragazzi; Soudabeh Vatankhah

17

Towards hepatitis C virus elimination in Iran: A blueprint for comprehensive strategies

Journal of Viral Hepatitis 31(9) (2024)

SeyedehFatemeh Mousavi; Maryam Alavi; Alireza Delavari; Hossein Poustchi; Zahra Mohammadi; Reza Malekzadeh

19

Non-healthcare costs of hepatitis C: a systematic review

Expert Review of Gastroenterology & Hepatology 12(1) (2018)

Natàlia Pascual-Argente; Jaume Puig-Junoy; Anna Llagostera-Punzano

20

Economic Burden of Hepatitis C Infection

Clinics in Liver Disease 21(3) (2017)

Maria Stepanova; Zobair M. Younossi

21

Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China

Hepatitis Monthly 20(3) (2020)

Dangui Zhang; Xubin Zhang; Lu Xu; D. Lorne Tyrrell; Michael Houghton; William Ba-Thein

22

Cost-of-illness analysis of ulcerative colitis patients treated with biological therapy: a prospective observational study in Iran

BMC Health Services Research 25(1) (2025)

Hassan Karami; Amin Ghanbarnejad; Mitra Nowrouzpour; Ali Mouseli; Reihaneh Taheri Kondar; Maryam Shirvani Shiri; Farbod Ebadi Fard Azar

23

Clinical Efficacy and Safety of Direct-Acting Antivirals in Chronic Hepatitis C Treatment: Real-World Data

Viral Hepatitis Journal 29(3) (2023)

Ayla Doğrugörün; Elif Doyuk Kartal; Saygın Nayman Alpat

24

Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules

Hepatitis Monthly In Press(In Press) (2019)

Figen Sarıgul; Murat Sayan; Ulku User; Nefise Oztoprak

25

Societal Economic Burden of Cystic Fibrosis in Iran: A Cost-of-Illness Study

Journal of Health Economics and Outcomes Research (2025)

Hassan Karami; Shideh Rafati; Maryam Shiri; Ali Mouseli; Hedayat Salari; Amin Ghanbarnejad; Mitra Mowrouzpour; Fatemeh Noroozian; Ali Alizadeh; Fatemeh Asadi; Narges Salehi